Lou and Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois, United States
Dr. Roger Stupp is an internationally renowned neuro-oncologist and a leading authority on primary and metastatic brain cancer, lung cancer and head & neck tumors. He trained as a physician and internist in Switzerland, followed by a Fellowship in Hematology/Oncology at the University of Chicago. He filled numerous roles at the University of Lausanne and more recently as the director of the Department of Oncology at the Zurich University Hospital, before joining in 2017 the team at Northwestern University in Chicago. Dr. Stupp served as the president of the European Organization for Research and Treatment of Cancer (EORTC) from 2012 – 2017, and remains a member of the board and executive committee.
Dr. Stupp is best known for establishing the use of temozolomide chemotherapy in conjunction with radiotherapy in patients with newly diagnosed glioblastoma, a treatment that rapidly became the worldwide standard of care and remains the backbone of glioma therapy to this date. Together with Monika Hegi, PhD and head of the laboratory of Tumor Biology and Genetics at the University of Lausanne/Switzerland they established MGMT as a predictive marker to identify tumors that respond to TMZ chemotherapy. And most recently Dr. Stupp and his colleagues demonstrated Tumor Treating Fields, an entirely novel cancer treatment modality prolongs survival in patients suffering from glioblastoma, a now FDA approved treatment.